Autopsy report · NCT01368536
Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes
Cause of deathOther
“Based on results from an ALTITUDE study interim analysis, testing aliskiren concomitantly with an ACE inhibitor or ARB, in diabetics with renal impairment”
Life of this trial
- Ran for about 9 months before it stopped.
- 975 participants enrolled.
- Results were posted on the registry 1 year 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 4
- Sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry
- Conditions
- Hypertension; Stage 2 Hypertension; Diabetes
- Interventions
- Valturna; Amlodipine; Chlorthalidone; Placebo of Valturna Tablet; Placebo Capsule
- Participants
- 975
- Sites
- 97
- Countries
- Puerto Rico, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.